ChemoCentryx is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of orally administered therapeutics targeting the chemokine and chemoattractant systems to treat autoimmune diseases, inflammatory disorders and cancer. The company has generated multiple clinical and preclinical-stage programs – each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds – based on its proprietary drug discovery and drug development platform. For more information, visit the company’s Web site at www.chemocentryx.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: